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Abstract: 
We examined the relationship between abdominal visceral fat (AVF) and plasma concentrations 
of lipids and lipoproteins in 19 females (F) (not on estrogen) and 31 males (M) over the age of 
60 (age = 66.8 years). In addition, the effects of growth hormone (GH) release, fitness (V˙O2 
peak), insulin, and glucose concentrations (both fasting and in response to an oral glucose 
tolerance test) on lipids were examined. Subjects were categorized by low (L) and high (H) AVF 
(L < 130 cm
2
, H > 130 cm
2
), fat mass (FM) (above or below median value), and AVF corrected 
for fat mass. Factorial analysis of variance (ANOVA) showed that when subjects were divided 
by AVF and FM, similar results were observed with H > L (P < .05) for very–low-density 
lipoprotein-cholesterol (VLDL-C), triglycerides (TG), VLDL-TG, apolipoprotein (apo)-B, apo-B 
VLDL, cholesterol (Chol)/highdensity lipoprotein (HDL), LDL/HDL, apoB/A1 and L > H for 
HDL, HDL2, HDL3, apo A1, and LDL/apo-B LDL. Gender differences were also observed with 
F > M for Chol, LDL, HDL, and HDL2. When AVF was corrected for FM, these gender 
differences were still present. After correcting for FM, differences remained between H and L 
AVF groups for VLDL, TG, VLDL-TG, apo-B, apo-B LDL, apo-B VLDL, apoB/A1 (P < .05). 
Twenty-four hour integrated GH concentration (IGHC) was inversely related to VLDL, TG, 
VLDL TG, LDL TG, apoB, apoB VLDL, apoB LDL, Chol/HDL, LDL/HDL, and apoB/A1 in F, 
but not M (P < .05). V˙O2 peak was directly related to Chol, LDL, HDL3, and apoB LDL with 
stronger relationships observed in F. Fasting insulin was related to lipids and lipoproteins in both 
men and women. These data suggest that, in older adults, elevated levels of AVF, FM, and AVF 
corrected for FM are associated with unfavorable lipid-lipoprotein profiles and extend similar 
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findings reported in younger males and females with elevated AVF. These data also support 
previous findings indicating that AVF is a primary determinant of GH release. 
 
Article: 
There is substantial circumstantial evidence to link abdominal visceral fat (AVF) to increased 
risk for diabetes and coronary artery disease in younger and obese individuals.
1-14
 Most of these 
studies have categorized subjects as having either high or low AVF, with those subjects with 
high AVF exhibiting increased risk for diabetes and coronary artery disease (CAD).
7-13
 However, 
when reporting a relationship between AVF and risk factors for disease, it is important to control 
for the concomitant effect of total body fat. 
 
In addition to the confounding effects of total body fat, gender differences have been observed in 
younger individuals with men having almost twice the amount of AVF for a given body fat mass 
(FM) as women.
15
 After controlling for gender dimorphism in AVF, it was found that most of the 
differences observed in plasma glucose-insulin homeostasis and in plasma lipoprotein-lipid 
profiles were no longer significant between men and women. 
16
 Although few studies have 
addressed these relationships in older individuals, DiPietro et al
17
 recently reported that in 
healthy older women, elevated AVF was associated with decreased high-density lipoprotein-
cholesterol (HDL-C) and an increase in the total/HDL-C ratio. 
 
AVF increases with age in both men and women. This increase is present in normal weight as 
well as in overweight and obese individuals. 
18-20
 It has been suggested that the increased 
cardiovascular risk observed in older adults may be mediated, in part, by increased AVF.
21
 
However, few data are available that examine the relationship between AVF and serum lipid and 
lipoprotein profiles (potent risk factors for CAD) in non-obese older adults. Several endocrine 
changes associated with age may contribute to the observed increase in AVF. These include 
elevated secretion of corticotropin (ACTH) and cortisol, decreased secretion of sex-specific 
steroid hormones (particularly in men), and diminished growth hormone (GH) secretion (for a 
recent review, see Bjorntorp
22
). We have recently reported that in both younger and older 
individuals the amount of AVF is a primary determinant of 24-hour GH secretion.
23
 Others have 
reported that administration of GH to GH-deficient and obese individuals resulted in a larger 
relative decrease in AVF than in subcutaneous fat. 
24,25
 Administration of GH to GH-deficient 
adults and obese men has also been shown to result in favorable alterations in total cholesterol, 
low-density lipoprotein-cholesterol (LDL-C), HDL-C, and apolipoprotein (apo)B 
.25-27
 It has also 
been suggested that GH may play an important role in lipid metabolism in healthy elderly 
individuals,
28,29
 as well as in GH-deficient adults,
30
 and that the neuroregulation of GH secretion 
is altered in premenopausal women with visceral obesity.
31 
 
In the present study, we examined the relationship between lipids and lipoproteins and AVF, 
total body fat, and AVF corrected for total body fat, in older (≥ 60 years) men and women. We 
hypothesized that similar to observations in younger adults, non-obese older men and women 
with elevated AVF (> 130 cm
2
)
14
 (as a result of aging rather than obesity) would exhibit 
unfavorable lipid and lipoprotein profiles compared with older adults with lower AVF. Based on 
our previous findings regarding AVF and GH,
23
 we further hypothesized that elevated AVF in 
older men and women would be associated with reduced 24-hour GH release and elevated 
insulin and glucose concentrations. 
MATERIALS AND METHODS  
Subjects and Study Protocol 
The study design was approved by the Human Investigation and General Clinical Research 
Center (GCRC) Advisory Committees of the University of Virginia, and each subject provided 
written informed consent in accordance with the guidelines established by the University of 
Virginia Human Investigation Committee. Fifty healthy older (31 men and 19 women; 60 to 79 
years old) adults volunteered as subjects. Participants included in this study were recruited by 
local media advertisement for participation in an ongoing investigation at the GCRC. All 
subjects completed a detailed medical history and underwent a physical examination before 
participation. None of the volunteers were taking medications known to affect serum lipids, 
glucose metabolism, GH secretion, or body composition measures, including exogenous use of 
estrogen (ie, estrogen replacement therapy) or lipid- lowering drugs. The older women included 
in this investigation were all postmenopausal. All subjects were nonsmokers and had not under-
taken transmeridian travel for at least 4 weeks. All data were collected within a 1-week time 
frame. 
 
Testing Procedures 
Graded exercise testing. V~O2 peak was determined using a graded maximal exercise (treadmill; 
Quinton Q65, Seattle, WA) test. Subjects were instructed to begin walking on the treadmill at an 
initial velocity that varied between 60 to 100 mlmin (self-selected). Velocity was increased every 
3 minutes by 10 mlmin until the subject reached volitional exhaustion. Metabolic measures were 
collected during the exercise bout via indirect calorimetry (open circuit spirometry) using a 
SensorMedics 2900-Z metabolic cart (Yorba Linda, CA). 
 
AVF. AVF (cm
2
) was determined from a single abdominal computed tomography (CT) scan 
performed at L4-L5. Scans were performed using a Picker PQ 5000 and analyzed using a newly 
developed tissue quantification analysis package using a Picker Voxel Q 3D imaging station 
(Picker International, Cleveland, OH) as described previously .32 The scanning was performed 
with 140 kV and a slice thickness of 0.5 cm. Briefly, the subjects were clothed only in a loose 
gown and examined in a supine position with their arms stretched above their head. An 
abdominal scan at the level of the L4-L5 inter- vertebral space was performed with no angulation 
using a lateral pilot for location. AVF cross-sectional areas (cm
2
) were calculated by delineating 
with a mouse computer interface the designated areas and then computing the adipose tissue area 
using an attenuation range from -190 to -30 Hounsfield units (HU). The measurement boundary 
for AVF was the internal most aspect of the abdominal and oblique muscle walls and the 
posterior aspect of the vertebral body [AVF-1
32
]. All CT scan analyses were performed by a 
single trained investigator (J.L.C.). 
 
Total body FM and total body percentage fat measurements. Body density was assessed by 
hydrostatic weighing (HW), corrected for measured residual lung volume, as previously 
described.
33
 Briefly, subjects were weighed in air on an Accu-weigh beam scale (accurate to 0.1 
kg; Metro Equipment, Sunnyvale, CA) and subsequently weighed underwater with a 9-kg 
Chatillon autopsy scale (accurate to 10 g; Chatillon, New York, NY). Water temperature was 
maintained between 35°C and 37°C. Underwater weight was measured at residual lung volume 
for 5 to 10 trials. The average of the last 3 trials was used for body density determination.
33
 
Residual lung volume was measured on land using an oxygen-dilution technique.
34
 The 
computational procedure of Siri
35
 was used to determine percentage body fat (% fat) from body 
density measurements. Because of concerns associated with body density determination by HW 
in the elderly, we examined data on 13 older subjects (7 women, 6 men) who had body density 
determined on at least 2 occasions. The mean difference between body density measures was 
0.009 glmL, the correlation coefficient was r = .97, and the total error (TE) was ± 0.0052 glmL.
36
 
In addition, because of reported limitations regarding assumptions underlying the constituents of 
the FM and fat-free mass (FFM) compartments when using a 2-compartment HW model in older 
adults, a subset of 33 subjects had their body composition measured using a 4-compartment 
model.
36 
 
Blood Sampling Procedures 
GH release. Twenty-four hour integrated GH concentrations (24-h IGHC; AglL • min) were 
determined for each subject. The subjects were admitted to the GCRC the evening before blood 
sampling. The following morning, a venous cannula was inserted into a forearm vein of each arm 
at 6:30 AM, and blood samples were obtained at 10-minute intervals for 24 hours (from 8 AM on 
day 1 to 8 AM on day 2) for later measurement of GH. Standardized meals (30% fat, 15% 
protein, and 55% carbohydrate) were served at 8 AM, 12 noon, and 6 PM. Total daily caloric 
requirements were determined from basal metabolic rate (BMR) measurements (Delta Trac I, 
Sensor Medics) performed for 30 minutes (6 to 6:30 AM) and corrected for differences in 
physical activity patterns by using widely-recognized adjustment factors ranging from 1.3 to 1.5. 
Volunteers were permitted to ambulate, but were not allowed to nap or sleep until 10 PM during 
the blood sampling. During the sleeping hours, blood samples were obtained via a 12-ft double 
lumen catheter kept patent by a heparinized (5,000 UlL) saline solution infused at 30 mLlh using 
previously described procedures.
37 
 
Fasting insulin, insulin-like growth factor-I, and steroid concentrations. Insulin and serum 
insulin-like growth factor (IGF)-I concentrations were determined from blood samples drawn 
after an overnight fast of 10 to 11 hours at approximately 7 AM during the day of blood 
sampling for 24-hour GH release. In addition, blood samples were drawn at 6-hour intervals (8 
AM, 2 PM, 8 PM, and 2 AM) and pooled for the measurement of estradiol and total testosterone. 
 
Oral glucose tolerance test. To assess glucose tolerance, 100 g glucose was administered on a 
separate day at 8 AM after an overnight fast of 10 to 11 hours. Blood samples for the 
measurement of glucose and insulin were obtained at -30, 0, 30, 60, 90, 120, 150, and 180 
minutes and analyzed using a Beckman (Fullerton, CA) automated glucose analyzer. Glucose 
area under the curve (AUC) and insulin AUC were determined using the trapezoidal rule. 
 
Hormonal assays. GH concentrations in all serum samples were measured using a 
chemiluminescence assay (Nichols Luma Tag hGH; Nichols Institute Diagnostics, San Juan 
Capistrano, CA) modified to enhance the sensitivity to 0.002 µglL.
38
 This assay detects predomi-
nantly the 22-kd form of GH, with 34% cross-reactivity for 20 kd GH (methionylated). The 
median intra-assay and interassay coefficients of variation were 4.7% and 8.6%, respectively. 
 
Fasting insulin and insulin concentrations during the oral glucose tolerance test (OGTT) were 
measured in the University of Virginia Diabetes Core Laboratory by a radioimmunoassay (RIA) 
method with a sensitivity of 11 pmol/L; the interassay CV was 11% at 49 pmollL and 5.9% at 
100 pmol/L. Serum IGF-I concentrations were measured in the University of Virginia GCRC 
Core Laboratory by RIA after acid- ethanol extraction (Nichols Institute Diagnostics). The 
median intraassay and interassay CVs were 2.7% and 6.8%, respectively. The pooled E2 and 
total T concentrations were determined in the University 
 
of Virginia GCRC Core Laboratory using a RIA (Diagnostic Products Corporation, Los Angeles, 
CA). This assay is known to have 10% cross-reactivity with estrone. Median intra-and interassay 
coefficients of variation were 3.9% and 9.5% for estradiol, and 6.9% and 10.3% for total 
testosterone. In addition, hematology, serum chemistries, thyroid function tests, and urinalyses 
were performed in the University of Virginia Health Sciences Center Clinical Laboratories using 
routine methods. 
 
Lipids and lipoproteins. Blood samples were obtained after an overnight fast of at least 12 hours. 
Cholesterol (Chol) and triglyceride (TG) levels were determined in plasma and in lipoprotein 
fractions by enzymatic methods using the Technicon RA-500 analyzer (Bayer Corporation, 
Tarrytown, NY) as previously described.
39
 Plasma very–lowdensity lipoprotein (VLDL) (d < 
1.006 glmL) were isolated by ultra- centrifugation, and the HDL fraction was obtained after 
precipitation of LDL in the infranatant (d > 1.006 glmL) with heparin and MnCl2 .40 The chol 
and TG contents of the infranatant fraction were measured before and after the precipitation step. 
The apo A-1 concentration was measured in the infranatant and apo B in the plasma and 
infranatant by the rocket immunoelectrophoretic method of Laurell
41
 as previously described.
42
 
The lyophilized serum standards for apo measurements were prepared in the core laboratory at 
the Lipid Research Center of Laval University Medical Center and calibrated with reference 
standards obtained from the Centers for Disease Control (Atlanta, GA). The chol content of 
HDL2 and HDL3 subfractions was also determined after further precipitation of HDL2 with 
dextran sulfate.
43
 Reproducibility of all lipid-lipoprotein measurements has been examined and 
found to be excellent with all lipid and lipoprotein variables having intraclass correlation 
coefficients (ICC) above 0.79.
44 
 
Statistical Analyses 
Subjects were categorized by low (L) and high (H) AVF (L < 130 cm
2
, H > 130 cm
2
; based on 
data suggesting increased risk for CAD above this threshold
1 4
), FM ( L < 25 kg for males, < 30 
kg for females; H > 25 kg for males, > 30 kg for females, based on the median values), and AVF 
corrected for FM. For AVF and FM, 2-way analysis of variance (ANOVA) (Sex X HlL 
category) was used to analyze the data. To correct AVF for FM, analysis of covariance 
(ANCOVA) was applied with AVF adjusted for FM. Due to missing data, insulin AUC was not 
included in these analyses. For each outcome the type I error rate for between group comparisons 
was adjusted by a least significant difference (LSD) criterion with comparison type I error rate of 
0.05. 
 
Correlation analyses were also applied to examine the relationships between the lipid and 
lipoprotein measures and AVF, FM, 24-h IGHC, VO2 peak, IGF-I, fasting insulin, glucose AUC, 
and insulin AUC. 
 
RESULTS 
Figure 1 shows the relationship between AVF and FM in older men and women. A constant 
difference in AVF between older men and women was observed at a given level of FM. That is, 
for any level of total body fat, older men had AVF values that were approximately 30 cm
2
 
greater than older women. 
 
Table 1 shows descriptive characteristics for body composition, V~O2 peak, fasting insulin, 
glucose AUC, 24-h IGHC, IGF-I, sex steroids, lipids, and lipoproteins in older females and 
males categorized by low (< 130 cm
2
) and high (> 130 cm
2
) AVF. When subjects were 
categorized by AVF, significant main effects were observed for both sex and AVF groups. Older 
females had higher values than older males for % fat, FM, 24-h IGHC, Chol, LDL Chol, HDL 
Chol, HDL2 Chol, and LDL/apo B LDL, whereas males had higher values than females for 
weight, height, AVF, V~O2 peak, total testosterone, estradiol, and fasting insulin. When AVF 
groups were examined, the high AVF group had values that were greater than those observed in 
the low AVF group for weight, BMI, % fat, FM, AVF, fasting insulin, VLDL Chol, TG, VLDL 
TG, LDL TG, apo B, apo B VLDL, Chol/HDL, LDL/HDL, and apo B/A1. The low AVF group 
had higher values for 24-h IGHC, total testosterone, HDL Chol, HDL2 Chol, and LDL/apo B 
LDL. No significant sex by AVF group interactions were observed, although the sex by AVF 
interaction for testosterone approached statistical significance (P < .07). 
 
Similar results were observed when subjects were divided by high FM (> 30 kg for females and 
> 25 kg for males) and low FM (< 30 kg for females and < 25 kg for males) (data not shown). 
When subjects were categorized by FM, significant 
 
main effects were observed for both sex and FM group. Females had higher values than males 
for % fat, FM, Chol, LDL Chol, HDL Chol, HDL2 Chol, apo B, apo B LDL, and apo A1, 
whereas males had higher values than females for weight, height, BMI, AVF, V~O2 peak, total 
testosterone, estradiol, and fasting insulin. When FM groups were examined, the high FM group 
had values that were greater than those observed in the low FM group for weight, % fat, FM, 
AVF, fasting insulin, VLDL Chol, TG, VLDL TG, apo B VLDL, Chol/HDL, LDL/ HDL, and 
apo B/A1. The low FM group had higher values for 24-h IGHC, V~O2 peak, HDL Chol, HDL2 
Chol, HDL3 Chol, apo A1, and LDL/apo B LDL. A significant sex by FM group interaction was 
observed for bdoy mass index (BMI) with the difference in BMI between the low and high 
female FM groups being greater than the low and high male FM groups (7.5 v 2.7 kg/m
2
, 
respectively). A sex by FM group interaction approached significance for 24-h IGHC and total 
testosterone (P < .07). No other interactions were observed when subjects were grouped by FM. 
In the subset of 33 subjects who had FM determined with a 4-compartment model of body 
composition, similar results were observed. 
 
To examine the effects of AVF independent of FM, ANCOVA was run with AVF adjusted for 
FM. When subjects were categorized by AVF adjusted for FM, significant main effects were 
observed for both sex and AVF group (Table 1). Females had higher values than males for % fat, 
24-h IGHC, Chol, LDL Chol, HDL Chol, HDL2 Chol, HDL3 Chol, apo A1, and LDL/apo B 
LDL, whereas males had higher values than females for weight, height, BMI, AVF, V~O2 peak, 
total testosterone, estradiol, and fasting insulin. When AVF adjusted for FM group was 
examined, the high AVF for FM group had values that were greater than those observed in the 
low AVF for FM group for AVF, fasting insulin, VLDL Chol, TG, VLDL TG, apo B, apo B 
VLDL, apo B LDL, Chol/HDL and apo B/A1. The low AVF for FM group had higher values for 
24-h IGHC. Significant sex by AVF for FM group interactions were observed for BMI and % 
fat. 
 
When sex steroid concentrations were examined within gen- 
 
der, a significantly higher testosterone concentration was observed within the low AVF males 
(16.6 ± 4.5 nmol/L) compared with the high AVF males (13.2 ± 3.1 nmol/L) (P < .02). 
 
To further examine the independent effects of AVF on insulin, 24-h IGHC, and serum lipids and 
lipoproteins in older adults, we were able to match 7 pairs of male subjects who had similar FM 
(means = 24.5 kg for both groups), but either low or high AVF (means of 90.4 v 162.2 cm2). 
With this limited number of subjects, we still observed trends for differences (low v high AVF) 
in fasting insulin (65.5 v 98.3 pmol/L, P = .10), 24-h IGHC (980 v 470 µg/L X min, P = .003), 
testosterone (16.7 v 12.9 nmol/L, P = .10), TG (1.39 v 2.08 mmol/L, P = .07), apo B (0.95 v 1.12 
mmol/L, P = .03), apo B LDL (0.88 v 1.00 mmol/L, P = .07), and apo B/A1 (0.81 v 0.91, P = 
.10). 
 
The relationship between the lipid and lipoprotein measures and body composition, fitness, 
insulin, glucose, 24-h IGHC, IGF-I, and sex steroids is shown in Tables 2 (older females) and 3 
(older males). When body composition variables were examined, FM and AVF had the strongest 
relationships with lipids and lipoproteins. The strength of the relationships and the number of 
significant correlations were greater in women than men. VO2 peak was related to LDL, HDL3, 
and apoB LDL with stronger relationships observed in women. 
 
Fasting insulin was directly related to VLDL Chol, TG, VLDL TG, LDL TG, HDL TG, apo B 
VLDL, Chol/HDL, LDL/HDL and apo B/A1 and inversely related to HDL, HDL2, and LDL/apo 
B LDL (Tables 2 and 3). The strength of these relationships and the number of significant 
correlations were greater in women than men. In contrast, significant relationships between 
insulin AUC during the OGTT and lipids and lipoproteins were observed only in the men 
(Table3), whereas glucose AUC showed little relationship to lipids and lipoproteins. 
 
The association of 24-hour GH release on lipids and lipoproteins was also examined. Inverse 
relationships were observed between 24-h IGHC and VLDL-C (females), TG (females), VLDL 
TG (males and females), LDL TG (females), apo B (females), apo B VLDL (males and females), 
apo B LDL (females), Chol/HDL (females), and LDL/HDL (females) and a direct relationship 
was observed between 24-h IGHC and LDL/ apo B LDL (males). The strength of the 
relationships and the number of significant correlations between 24-h IGHC and measures of 
lipids and lipoproteins was greater in women than men (Tables 2 and 3). 
 
DISCUSSION 
Many studies in younger and obese adults have demonstrated that men and women have, on 
average, marked differences in regional fat distribution, 
15,16
 lipoprotein profiles,6-8,12-14 and 
indices of glucose-insulin homeostasis.
5,6,9-12,16
 Our results in older subjects (age 60 years and 
over) agree with these previous reports. Older men and women with higher levels of AVF had 
unfavorable lipid and lipoprotein profiles, higher fasting insulin levels, lower total testosterone 
levels (particularly in older men), and lower 24-h IGHC (Table 1). Gender differences observed 
previously in younger adults were also seen in our older subjects. In the present study, older men 
had higher levels of AVF and fasting insulin levels and lower 24-h IGHC, total cholesterol, LDL 
chol, HDL-C, HDL2-C, HDL3- C, apo A1 concentrations, and LDL/apo B LDL in comparison 
with older women (Table 1). It has been suggested that AVF is a major contributor to the 
observed gender difference in hepatic lipase activity, although other gender-related differences 
may have an impact. 
45
 The higher hepatic lipase activity observed in men is thought to affect 
both LDL and HDL heterogeneity and may thus be associated with increased CAD risk in 
men.45 
 
 
Other aspects of the association between body fat distribution and dyslipidemia has been 
described in detail.
46
 Although subjects with high AVF exhibit increased risk for diabetes and 
CAD,
7-13
 when reporting the relationship between AVF and risk factors for disease, it is 
important to control for the concomitant effect of total body fat. In the present study, unfavorable 
endocrine and lipoprotein profiles were observed in subjects with higher absolute levels of FM or 
AVF compared with subjects with lower levels of FM or AVF. In addition, AVF and FM were 
both significantly correlated with lipid and lipoprotein levels, with stronger relationships 
observed in older women than in older men (Tables 2 and 3). This makes it difficult to discern 
the independent effects of AVF and FM on these measures. However, when AVF was corrected 
for FM, unfavorable lipid and lipoprotein profiles were still observed (Table 1). These data 
suggest that, similar to observations in young and obese adults,
46
 abdominal visceral obesity in 
older adults is associated with several changes in the metabolic profile predictive for increased 
risk for metabolic complications. It should be noted that the relationship between AVF and FM 
appears to be altered in older adults. Although gender differences still exist, they are not as 
marked as observed in younger adults. That is, in younger adults the slopes of the regression 
lines relating AVF to FM were greater in men, with men having almost twice the amount of AVF 
for a given amount of body FM as premenopausal women. 
15
 In the present study, no gender 
differences were observed in older adults for the slopes of the regression lines relating AVF to 
FM. Rather, a constant difference of — 30 cm
2
 greater AVF for any given amount of FM was 
observed in older men compared with the older women (Fig 1). 
 
Elevated TG, apo B, and fasting insulin were among the unfavorable risk factors associated with 
elevated AVF in the present sample of older adults. These findings have clinical implications for 
increased risk of CAD in older adults with elevated AVF. The nontraditional risk factors of 
fasting insulin, apo B levels and small dense LDL size (fasting TG concentrations > 2.0 mmol/L 
are associated with an increase in small dense LDL particle size
47
) have been shown to provide 
more information on CAD risk than the more traditional lipid risk factors of LDL Chol, TG, and 
HDL Chol.
42
 Lamarche et al
47
 reported that almost 1 in every 2 ischemic heart disease cases had 
elevated concentrations of insulin, apo B, and small dense LDL particles, and that this 
combination of metabolic risk factors resulted in an 18-fold increase in the risk of ischemic heart 
disease. Furthermore, adjustment for the more traditional cluster of lipid risk factors did not 
attenuate this relationship. If one examines the traditional lipid risk factors in the present study, 
one might conclude that elevated AVF does not increase CAD risk in older adults. That is, when 
AVF was corrected for FM, no significant differences were observed for HDL Chol, and LDL-C 
between high and low AVF groups (Table 1). However, elevated AVF was associated with 
higher concentrations of apo B, fasting insulin, and TG. In particular, the mean TG concentration 
exceeded 2.0 mmol/L in older subjects with elevated AVF (Table 1), suggesting that small dense 
LDL particles were elevated in these individuals. These data suggest that elevated AVF in older 
adults is potentially associated with an increased risk of CAD. 
 
Several potential mechanisms have been proposed to explain the relationship between increased 
AVF and unfavorable lipid and lipoprotein profiles. It has been suggested that the dyslipidemic 
state associated with visceral obesity results from complex metabolic and hormonal interactions 
that lead to insulin resistance and increased risk of CAD.
46
 Enlarged omental fat cells display a 
high lipolytic activity that is poorly inhibited by insulin.
3
 It has been hypothesized that this 
contributes to a greater flux of free fatty acids in the portal circulation resulting in reduced 
hepatic insulin extraction,
48
 hyperinsulinemia, increased VLDL synthesis, and apo B 
production.
3,46
 Visceral obesity is also associated with reduced lipoprotein lipase (LPL) levels, 
which in combination with increased VLDL synthesis, results in elevated plasma concentrations 
of TG-rich lipoproteins. Higher TG-rich lipoprotein levels are associated with an increased 
transfer of TG from VLDL to LDL or HDL particles leading to TG enrichment of LDL and 
HDL.
8
 This TG enrichment of LDL and HDL is associated with a reduction in HDL Chol and 
also provides a good substrate for hepatic TG lipase, ultimately resulting in the generation of 
small dense LDL particles.
46
 The present findings of elevated fasting insulin, VLDL-C, VLDL 
TG, LDL TG, apo B, and apo B VLDL and reduced HDL-C and HDL2-C in older adults with 
elevated AVF (Table 1) support this hypothesis. 
 
Several endocrine abnormalities in addition to hyperinsulinemia have been described in 
individuals with elevated visceral fat.
22
 It has been suggested that enhanced sensitivity of the 
hypothalamo-pituitary-adrenal axis results in increased secretion of corticotropin-releasing 
hormone, ACTH, cortisol, and in women, adrenal androgens .22 In addition, individuals with el-
evated AVF have lower serum GH and sex steroid concentrations.
22,23
 The combination of 
elevated cortisol and insulin concentrations coupled with reduced GH and sex steroids levels 
observed in individuals with elevated AVF is thought to exert powerful effects leading to 
increased serum TG concentrations.
22
 With aging, serum concentrations of GH, testosterone (in 
men), and estrogen (in postmenopausal women) decline. These endocrine changes with aging are 
thought to contribute to the increase in AVF observed with age .22 Our observations of an 
inverse relationship between AVF and 24-h IGHC (r = -.60 and r = -.65 in women and men, 
respectively) coupled with lower 24-h IGHC, lower testosterone levels, and higher fasting insulin 
concentrations in older individuals with elevated AVF are consistent with reports in younger 
individu als with the metabolic syndrome. In support of this notion, we recently reported that in 
both younger and older individuals AVF was a primary determinant of 24-hour GH release .23 
Furthermore, administration of GH
25
or testosterone
49
 to abdominally obese adults results in a 
reduction in AVF and an improvement in glucose and lipoprotein metabolism. 
 
It has also been suggested that GH may have direct effects on lipid and lipoprotein 
metabolism.
24-29,50
 The proposed mechanism of this direct effect of GH is the ability of GH to 
induce hepatic LDL receptor expression.
29
 This would result in an increased clearance of LDL 
Chol as well as an increased clearance of VLDL apo B, because the LDL receptor is involved in 
the hepatic removal of partially depleted VLDL.
29
 Thus, it is possible that decreased GH 
secretion may contribute to the unfavorable lipid profile observed in older adults with elevated 
AVF. 
 
In summary, results of the present study indicate that in older adults increased FM, AVF, and 
AVF corrected for FM were related to unfavorable lipid and lipoprotein profiles. In particular, 
these measures were associated with higher levels of nontraditional risk factors (fasting insulin, 
TG, and apo B), suggesting a higher risk of CAD. The higher fasting insulin concentrations and 
reduced 24-h IGHC associated with higher FM and AVF suggest that insulin and GH may be 
important mediators of the impact of these measures on lipid and lipoprotein metabolism. Sex 
steroids, particularly testosterone levels in older men, may modulate these relationships. 
 
ACKNOWLEDGMENT 
The authors would like to thank the following individuals: Sandra Jackson and the nurses of the 
University of Virginia GCRC for their expert clinical care; Ginger Bauler, Catherine Kern, Eli 
Casarez, and David Smith in the GCRC core laboratory for performing the GH 
chemiluminescence and other hormone assays; Susan Bird, Cathy Pritzlaff, and Kimberly Brill 
for technical assistance; Dr Margaret Gutgesell for her help with underwater weighing; and Dr C. 
David Teates and his staff for their assistance with CT measurements. 
 
REFERENCES 
1. Kissebah AH, Evans DJ, Perris A, et al: Endocrine characteristics in regional obesities: Role 
of sex steroids, in Vague J, Bjorntorp P, Guy-Grand B, et al (eds): Metabolic Complications of 
Human Obesities. Amsterdam, The Netherlands, Excerpta Medica, 1985, pp 115- 130 
2. Lapidus L, Bengtsson C, Bjorntorp P: The quantitative relationship between ―the metabolic 
syndrome' and abdominal obesity in women. Obes Res 2:372-377, 1994 
3. Bjorntorp P: ―Portal' adipose tissue as a generator of risk factors for cardiovascular disease 
and diabetes. Arteriosclerosis 10:493-496, 1990 
4. Goto T, Onumua T, Takebe K, et al: The influence of fatty liver on insulin clearance and 
insulin resistance in non-diabetic Japanese subjects. Int J Obes 19:841-845, 1995 
5. Banerji MA, Buckley C, Chaiken RL, et al: Liver fat, serum triglycerides and visceral 
adipose tissue in insulin-sensitive and insulin- resistant black men with NIDDM. Int J Obes 
19:846-850, 1995 
6. Fujioka S, Matsuzawa Y, Tokunga K, et al: Contribution of intra-abdominal fat 
accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism 
36:54-59, 1987 
7. Despres JP, Moorjani S, Ferland M, et al: Adipose tissue distri- 
bution and plasma lipoprotein levels in obese women: Importance of intra-abdominal fat. 
Arteriosclerosis 9:203-210, 1989 
8. Despres JP, Ferland M, Moorjani S, et al: Role of hepatictriglyceride lipase activity in the 
association between intra-abdominal fat and plasma HDL-cholesterol in obese women. 
Arteriosclerosis 9:485-492, 1989 
9. Sparrow D, Borkan GA, Gerzof SG, et al: Relationship of body fat distribution to glucose 
tolerance. Results of computed tomography in male participants of the normative aging study. 
Diabetes 35:411-415, 1986 
10. Perris AN, Sothmann MS, Hennes MI, et al: Relative contribution of obesity and body fat 
distribution to alterations in glucose insulin homeostasis: Predictive value of selected indices in 
premenopausal women. Am J Clin Nutr 49:758-764, 1989 
11. Despres JP, Nadeau A, Tremblay A, et al: Role of deep abdominal fat in the association 
between regional adipose tissue distribution and glucose tolerance in obese women. Diabetes 
38:304-309, 1989 
12. Pouliot MC, Despres JP, Nadeau A, et al: Visceral obesity in men. Associations with 
glucose tolerance, plasma insulin, and lipoprotein levels. Diabetes 41:862-834, 1992 
13. Despres JP, Moorjani S, Lupien PJ, et al: Regional distribution 
of body fat, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis 10:497-511, 1990 
14. Despres JP: Visceral obesity, insulin resistance and dyslipidemia: Contribution of 
endurance exercise training to the treatment of the plurimetabolic syndrome, in Holloszy JO (ed): 
Exercise and Sport Sciences Reviews. Baltimore, MD, Williams & Wilkins, 1977, pp 271-300 
15. Lemiux S, Prud’homme D, Bouchard C, et al: Sex differences in the relation of visceral 
adipose tissue accumulation to total body fatness. Am J Clin Nutr 58:463-467, 1993 
16. Lemuix S, Despres JP, Moorjani S, et al: Are gender differences in cardiovascular disease 
risk factors explained by the level of visceral adipose tissue? Diabetologia 37:757-764, 1994 
17. DiPietro L, Katz, LD, Nadel, ER: Excess abdominal adiposity remains correlated with 
altered lipid concentrations in older women. Int J Obes 23:432-436, 1999 
18. Bouchard C, Despres JP, Mauriege P: Genetic and nongenetic determinants of regional fat 
distribution. Endocr Rev 14:72-93, 1993 
19. Borkan GA, Norris AH: Fat redistribution and the changing dimensions of the adult male. 
Hum Biol 49:495-514, 1977 
20. Borkan GA, Hults DE, Gerzof SG, et al: Age changes in body composition revealed by 
computed tomography. J Gerontol 38:673- 677,1983 
21. Hunter, GR, Bryan DR, Wetzstein CJ, et al: Resistance training and intra-abdominal 
adipose tissue in older men and women. Med Sci Sports Exerc 34:1023-1028, 2002 
22. Bjorntorp P: Etiology of the metabolic syndrome, in Bray GA, Bouchard C, James WPT 
(eds): Handbook of Obesity. New York, NY, Marcel Dekker, 1998, pp 573-600 
23. Clasey JL, Weltman A, Patrie J, et al: Abdominal visceral fat, fasting insulin and IGF-I are 
important predictors of 24-hour growth hormone release independent of age, gender and other 
physiological factors. J Clin Endocrinol Metab 86:3845-3852, 2001 
24. Bengtsson BA, Eden S, Lonn L, et al: Treatment of adults with growth hormone (GH) 
deficiency with recombinant human GH. J Clin Endocrinol Metab 76:309-317, 1993 
25. Johannsson G, Marin P, Lonn L, et al: Growth hormone treatment of abdominally obese 
men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces 
diastolic blood pressure. J Clin Endocrinol Metab 82:727-734, 1997 
26. Johannsson G, Oscarsson J, Rosen T, et al: Effects of 1 year of growth hormone therapy on 
serum lipoprotein levels in growth hormone-deficient adults. Influence of gender and Apo(a) and 
ApoE phenotypes. Arteriosclerosis 15:2142-2150, 1995 
27. Colao A, Somma CD, Pivonello R, et al: The cardiovascular risk of adult GH deficiency 
(GHD) improved after GH replacement and worsened in untreated GHD: A 12-month 
prospective study. J Clin Endocrinol Metab 87:1088-1093, 2002 
28. Ceda GP, Dall’Aglio E, Magnacavallo A, et al: The insulin-like growth factor axis and 
plasma lipid levels in the elderly. J Clin Endocrinol Metab 83:499-502, 1998 
29. Vahl N, Klausen IB, Christiansen JS, et al: Growth hormone (GH) status is an independent 
determinant of serum levels of cholesterol and triglycerides in healthy adults. Clin Endocrinol 
51:309-316, 1999 
30. Abdu TAM, Neary R, Elhadd TA, et al: Coronary risk in growth hormone deficient 
hypopituitary adults: Increased predicted risk is due largely to lipid profile abnormalities. Clin 
Endocrinol 55:209-216, 2001 
31. Pijl H, Langendonk JG, Burggraaf J, et al: Altered neuroregulation of GH secretion in 
viscerally obese premenopausal women. J Clin Endocrinol Metab 86:5509-5515, 2001 
32. Clasey JL, Bouchard C, Wideman L, et al: The influence of anatomical boundaries, age, 
and sex on the assessment of abdominal visceral fat. Obes Res 5:395-401, 1997 
33. Katch FI, Micheal ED, Horvath SM: Estimation of body volume by underwater weighing: 
Description of a single method. J Appl Physiol 23: 811-816, 1967 
34. Wilmore JH: A simplified method for the determination of residual lung volume. J Appl 
Physiol 27:96-100, 1969 
35. Siri WE: Body composition from fluid spaces and density. Analysis of methods, in Brozer 
J, Henschel A (eds): Techniques for Measuring Body Composition. Washington, DC, National 
Academy of Sciences/National Research Council, 1961, pp 223-244 
36. Clasey JL, Kanaley JA, Wideman L, et al: Validity of methods of body composition 
assessment in young and older men and women. J Appl Physiol 86:1728-1738, 1999 
37. Hartman ML, Pezzoli SS, Hellmann PJ, et al: Pulsatile growth hormone secretion in older 
persons is enhanced by fasting without relationship to sleep stages. J Clin Endocrinol Metab 
81:2694-2701, 1996 
38. Chapman IM, Hartman ML, Straume M, et al: Enhanced sensitivity growth hormone 
chemiluminescence assay reveals lower post- glucose nadir GH concentration in men and 
women. J Clin Endocrinol Metab 78:1312-1319, 1994 
39. Moorjani S, Dupont A, Labrie F, et al: Increase in plasma high-density lipoprotein 
concentration following complete androgen blockage in men with prostatic carcinoma. 
Metabolism 36:244-250, 1987 
40. Burstein M, Samaille J: Sur un dosage rapide du cholesterol lié aux a- et beta-lipoprotéines 
du sérum. Clin Chim Acta 5:609-612, 1960 
41. Laurell CB: Quantitative estimation of proteins by electrophoresis in agarose gel containing 
antibodies. Anal Biochem 15:45-52, 1966 
42. Avogaro P, Bon GB, Cazzolato G, et al: Are apolipoproteins better discriminators than 
lipids for atherosclerosis? Lancet 1:901-903, 1979 
43. Gidez LI, Miller GJ, Burstein M, et al: Separation and quantitation of subclasses of human 
plasma high density lipoproteins by a simple precipitation procedure. J Lipid Res 23:1206-1223, 
1982 
44. Després JP, Gagnon J, Bergeron J, et al: Plasma post-heparin lipase activities in the 
HERITAGE Family Study—The reproducibility, gender differences and associations with 
lipoprotein levels. Clin Biochem 32:157-165, 1999 
45. Carr MC, Hokanson, JE, Zambon A, et al: The contribution of intraabdominal fat to gender 
differences in hepatic lipase activity and lowlhigh density lipoprotein heterogeneity. J Clin 
Endocrinol Metab 86:2831-2837,2001 
46. Despres JP, Krauss RM: Obesity and lipoprotein metabolism, in Bray GA, Bouchard C, 
James WPT (eds): Handbook of Obesity. New York, NY, Marcel Dekker, 1998, pp 651-675 
47. Lamarche B, Tchernof A, Mauriege P, et al: Fasting insulin and apolipoprotein B levels and 
low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA 279:1955-
1961, 1998 
48. Svedberg J, Bjorntorp P, Smith V, et al: FFA inhibition of insulin binding, degradation, and 
action in isolated rat hepatocytes. Diabetes 39:570-574, 1990 
49. Marin P, Holmang S, Jonsson L, et al: The effects of testosterone treatment on body 
composition and metabolism in middle-aged obese men. Int J Obes 16:991-997, 1992 
50. O’Connor KG, Harman SM, Stevens TE, et al: Interrelationships of spontaneous growth 
hormone axis activity, body fat, and serum lipids in healthy elderly women and men. Metabolism 
48:1424-1431, 1999 
